iCo Therapeutics and JDRF Partnership Goes Beyond Clinical Advancement

June 5, 2013, Vancouver, Canada – iCo and JDRF established a partnership in September 2011 when they joined forces on the iDEAL Study to improve outcomes for people affected by diabetic macular edema (DME).  Specifically, the study is evaluating iCo-007, a second-generation antisense inhibitor targeting the growth factors causing blindness in diabetic patients.  iDEAL is in phase 2 clinical testing and expects to announce primary endpoint data early in 2014. Today JDRF and iCo Therapeutics highlight this great relationship as they both participate in the 9th Annual TELUS Walk to Cure Diabetes, an event directed by JDRF.

“We are proud to be a corporate sponsor of the TELUS Walk to Cure Diabetes on June 9 and we have formed a walking team to raise additional funds for this great cause,” said Andrew Rae, President and CEO of iCo Therapeutics. “Our relationship with JDRF continues to grow and they have been fantastic and supportive of our iDEAL study for DME patients.  If successful, this drug will be a novel treatment for the symptoms and complications of DME and will ensure individuals in the diabetes community will have a more efficient treatment available to them.”

The condition of DME is a very serious complication that causes swelling and deformation to the eyes, and is the leading cause of vision impairment and blindness in people aged 20-74 years. The iDEAL study is being conducted across 27 clinical sites in the United States, with the ultimate goal to improve the quality of care for those experiencing this severe condition.

“This growing partnership aims to turn a transformational treatment into reality for individuals experiencing DME,” said Andrew McKee, President and CEO of JDRF Canada. “If approved, the treatment has the potential to help the diabetes community on a global scale. We are very happy to be partnered with iCo Therapeutics to make this study a reality and happy to have them as a corporate sponsor of the annual walk.”

JDRF is committed to developing new and better treatments that improve the lives of people with type 1 diabetes (T1D) in the near term, and keep them healthy while we advance toward a cure. The partnership with iCo Therapeutics for the iDEAL study is a glimpse into the ground-breaking research JDRF is proud to support that has the potential to drastically improve the quality of life for individuals experiencing diabetes complications.  


About JDRF  
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is the largest charitable supporter of T1D research. The goal of JDRF is to improve the lives of every person affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.7 billion to T1D research. Past JDRF research efforts have helped to significantly improve the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. 

For more information, please visit jdrf.ca.

About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The company has exclusive worldwide rights to two drug candidates – iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases.  iCo trades on the TSX Venture Exchange under the symbol “ICO”.  For more information, visit the Company website at: icotherapeutics.com.

For more information, or to schedule an interview, please contact:
Sara Marano, JDRF Canada
647.789.2027
smarano@jdrf.ca 

Lets turn type one into type none